MX2022005951A - Compuestos de pirrolotriazina que actuan como inhibidor de mnk. - Google Patents
Compuestos de pirrolotriazina que actuan como inhibidor de mnk.Info
- Publication number
- MX2022005951A MX2022005951A MX2022005951A MX2022005951A MX2022005951A MX 2022005951 A MX2022005951 A MX 2022005951A MX 2022005951 A MX2022005951 A MX 2022005951A MX 2022005951 A MX2022005951 A MX 2022005951A MX 2022005951 A MX2022005951 A MX 2022005951A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds acting
- pyrrolotriazine compounds
- mnk inhibitor
- inhibitor
- mnk
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cosmetics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Se describen compuestos de pirrolotriazina que actúan como un inhibidor de la cinasa que interactúa con la proteína cinasa activada por mitógeno (MNK), y el uso de los mismos en la preparación de un fármaco inhibidor de la cinasa que interactúa con la proteína cinasa activada por mitógeno. Específicamente se describen compuestos representados por la fórmula (I) o una sal farmacéuticamente aceptable de los mismos. (Ver formula I).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911129114 | 2019-11-18 | ||
| CN202010329964 | 2020-04-24 | ||
| PCT/CN2020/129603 WO2021098691A1 (zh) | 2019-11-18 | 2020-11-18 | 作为mnk抑制剂的吡咯并三嗪类化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022005951A true MX2022005951A (es) | 2022-07-27 |
Family
ID=75981354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022005951A MX2022005951A (es) | 2019-11-18 | 2020-11-18 | Compuestos de pirrolotriazina que actuan como inhibidor de mnk. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20220281895A1 (es) |
| EP (1) | EP4063364B1 (es) |
| JP (1) | JP7311207B2 (es) |
| KR (1) | KR102792835B1 (es) |
| CN (1) | CN114728966B (es) |
| AU (1) | AU2020387982B2 (es) |
| BR (1) | BR112022009563A2 (es) |
| CA (1) | CA3158749A1 (es) |
| DK (1) | DK4063364T3 (es) |
| ES (1) | ES2993664T3 (es) |
| FI (1) | FI4063364T3 (es) |
| HR (1) | HRP20241540T1 (es) |
| HU (1) | HUE068905T2 (es) |
| LT (1) | LT4063364T (es) |
| MX (1) | MX2022005951A (es) |
| PH (1) | PH12022551226A1 (es) |
| PL (1) | PL4063364T3 (es) |
| PT (1) | PT4063364T (es) |
| SI (1) | SI4063364T1 (es) |
| WO (1) | WO2021098691A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240254144A1 (en) | 2021-05-08 | 2024-08-01 | Jumbo Drug Bank Co., Ltd. | Salt form of pyrrolotriazine compound, crystal form thereof, and preparation method therefor |
| CN118785912A (zh) * | 2022-07-19 | 2024-10-15 | 成都嘉葆药银医药科技有限公司 | 一种吡咯并三嗪类化合物在制备抗肿瘤药物中的应用 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| CN119925378A (zh) * | 2023-11-03 | 2025-05-06 | 成都嘉葆药银医药科技有限公司 | 吡咯并三嗪类化合物在制备预防和/或治疗纤维化或其相关疾病的药物中的应用 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329112B (en) * | 2002-07-19 | 2010-08-21 | Bristol Myers Squibb Co | Novel inhibitors of kinases |
| US7405213B2 (en) * | 2005-07-01 | 2008-07-29 | Bristol-Myers Squibb Company | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith |
| WO2015091156A1 (en) * | 2013-12-17 | 2015-06-25 | Boehringer Ingelheim International Gmbh | Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions |
| TWI713455B (zh) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | ＭｎＫ抑制劑及其相關方法 |
| CN107750167B (zh) | 2015-04-20 | 2021-05-25 | 效应物治疗公司 | 用于治疗癌症和感染的免疫检查点调节剂的抑制剂 |
| EA034440B1 (ru) | 2015-10-29 | 2020-02-07 | Эффектор Терапьютикс, Инк. | СОЕДИНЕНИЯ ПИРРОЛО-, ПИРАЗОЛО-, ИМИДАЗОПИРИМИДИНА И ПИРИДИНА, КОТОРЫЕ ИНГИБИРУЮТ Mnk1 И Mnk2 |
| AU2016343687A1 (en) | 2015-10-29 | 2018-06-07 | Effector Therapeutics, Inc. | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of Mnk1 and Mnk2 |
| WO2017087808A1 (en) * | 2015-11-20 | 2017-05-26 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers |
| WO2017117052A1 (en) * | 2015-12-31 | 2017-07-06 | Effector Therapeutics, Inc. | Mnk biomarkers and uses thereof |
| WO2018134335A1 (en) * | 2017-01-20 | 2018-07-26 | Bayer Pharma Aktiengesellschaft | Substituted imidazopyridinpyrimidines |
| US20180228803A1 (en) | 2017-02-14 | 2018-08-16 | Effector Therapeutics, Inc. | Piperidine-Substituted Mnk Inhibitors and Methods Related Thereto |
| US10780119B2 (en) * | 2017-05-24 | 2020-09-22 | Effector Therapeutics Inc. | Methods and compositions for cellular immunotherapy |
| US20240254144A1 (en) * | 2021-05-08 | 2024-08-01 | Jumbo Drug Bank Co., Ltd. | Salt form of pyrrolotriazine compound, crystal form thereof, and preparation method therefor |
-
2020
- 2020-11-18 MX MX2022005951A patent/MX2022005951A/es unknown
- 2020-11-18 ES ES20889927T patent/ES2993664T3/es active Active
- 2020-11-18 CA CA3158749A patent/CA3158749A1/en active Pending
- 2020-11-18 FI FIEP20889927.8T patent/FI4063364T3/fi active
- 2020-11-18 AU AU2020387982A patent/AU2020387982B2/en active Active
- 2020-11-18 KR KR1020227020316A patent/KR102792835B1/ko active Active
- 2020-11-18 HU HUE20889927A patent/HUE068905T2/hu unknown
- 2020-11-18 PT PT208899278T patent/PT4063364T/pt unknown
- 2020-11-18 LT LTEPPCT/CN2020/129603T patent/LT4063364T/lt unknown
- 2020-11-18 SI SI202030527T patent/SI4063364T1/sl unknown
- 2020-11-18 HR HRP20241540TT patent/HRP20241540T1/hr unknown
- 2020-11-18 WO PCT/CN2020/129603 patent/WO2021098691A1/zh not_active Ceased
- 2020-11-18 PL PL20889927.8T patent/PL4063364T3/pl unknown
- 2020-11-18 EP EP20889927.8A patent/EP4063364B1/en active Active
- 2020-11-18 BR BR112022009563A patent/BR112022009563A2/pt unknown
- 2020-11-18 CN CN202080080586.0A patent/CN114728966B/zh active Active
- 2020-11-18 JP JP2022528959A patent/JP7311207B2/ja active Active
- 2020-11-18 DK DK20889927.8T patent/DK4063364T3/da active
- 2020-11-18 PH PH1/2022/551226A patent/PH12022551226A1/en unknown
-
2022
- 2022-05-18 US US17/664,026 patent/US20220281895A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4063364A1 (en) | 2022-09-28 |
| HRP20241540T1 (hr) | 2025-01-03 |
| KR20220101686A (ko) | 2022-07-19 |
| AU2020387982A1 (en) | 2022-06-30 |
| PL4063364T3 (pl) | 2025-01-20 |
| FI4063364T3 (fi) | 2024-11-19 |
| CN114728966B (zh) | 2023-08-18 |
| CN114728966A (zh) | 2022-07-08 |
| US20220281895A1 (en) | 2022-09-08 |
| EP4063364B1 (en) | 2024-09-25 |
| SI4063364T1 (sl) | 2025-02-28 |
| DK4063364T3 (da) | 2024-11-25 |
| WO2021098691A1 (zh) | 2021-05-27 |
| PT4063364T (pt) | 2024-10-30 |
| ES2993664T3 (en) | 2025-01-03 |
| JP7311207B2 (ja) | 2023-07-19 |
| JP2023502237A (ja) | 2023-01-23 |
| BR112022009563A2 (pt) | 2022-08-02 |
| AU2020387982B2 (en) | 2023-08-03 |
| CA3158749A1 (en) | 2021-05-27 |
| LT4063364T (lt) | 2024-11-11 |
| EP4063364A4 (en) | 2023-12-13 |
| KR102792835B1 (ko) | 2025-04-07 |
| PH12022551226A1 (en) | 2023-06-14 |
| HUE068905T2 (hu) | 2025-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022551226A1 (en) | Pyrrolotriazine compounds acting as mnk inhibitor | |
| SA520420033B1 (ar) | مركبات صيدلية | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| PH12019502245A1 (en) | Compounds that inhibit mcl-1 protein | |
| MX2020013817A (es) | Compuestos de naftiridinona sustituidos utiles como activadores de celulas t. | |
| AU2018271990A1 (en) | Covalent inhibitors of KRAS | |
| ZA202206923B (en) | New methylquinazolinone derivatives | |
| EA033689B9 (ru) | Ингибиторы g12c kras | |
| WO2016164675A8 (en) | Substituted quinazoline compounds and methods of use thereof | |
| CA2983481A1 (en) | Janus kinase inhibitor | |
| EP4541422A3 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| EA201000091A1 (ru) | ПРОИЗВОДНЫЕ МОРФОЛИНОПИРИМИДИНА, ИСПОЛЬЗУЕМЫЕ ПРИ ЗАБОЛЕВАНИЯХ, СВЯЗАННЫХ С mTOR КИНАЗОЙ И/ИЛИ PI3K | |
| MX2019009501A (es) | Compuestos de amino piridina utiles como inhibidores de ssao. | |
| EP4249071A3 (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| WO2014125408A3 (en) | Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors | |
| AU2020288567A8 (en) | Pyrrolopyrimidine compound and use thereof | |
| SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| MX389786B (es) | Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer. | |
| SA520411635B1 (ar) | A2a مشتق حلقي مدمج كمثبط مستقبل | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| ZA202401684B (en) | Novel parp7 inhibitor and use thereof | |
| AU2019296118A8 (en) | Isothiazolo(5,4-d)pyrimidine compound as IRAK4 inhibitor |